MNKD sentiment intelligence

MannKind Corp looks beyond inhaled insulin as pipeline ambitions grow

MannKind Corp is expanding its pipeline beyond its inhaled insulin product, Afrezza, by seeking new therapeutic applications for its Technosphere drug-delivery platform. While Afrezza remains the commercial foundation, the company is exploring other indications like pulmonary art

Tone

Positive 63/100

Event

Market update

Published

07 Jul 2026 14:41

Source

AD HOC NEWS

MannKind (MNKD) Receives a Grant from Breakthrough T1D

MannKind Corporation (MNKD) received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial, which evaluates inhaled insulin in newly diagnosed pediatric patients with type 1 diabetes. This grant provides external validation for Afrezza, MannKind's inhaled insulin

Tone

Positive 73/100

Event

Market update

Published

03 Jul 2026 13:09

Source

Insider Monkey

Is MannKind Corporation (MNKD) A Good Stock To Buy Now?

Tone

Positive 66/100

Event

Market update

Published

29 Jun 2026 07:00

Source

Market source

MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MannKind Corp (MNKD), noting its current price momentum score and suggesting suitability for range-bound swing trading as it trades between resistance at $4.17 and support at $3.41. It presents a summary of technical indicators and mo

Tone

Positive 67/100

Event

Market update

Published

25 Jun 2026 00:39

Source

TradingKey

Afrezza Pediatric Trial Grant Might Change The Case For Investing In MannKind (MNKD)

MannKind Corporation received a grant from Breakthrough T1D for its INHALE-1 clinical study of Afrezza in pediatric type 1 diabetes patients. This funding, combined with recent FDA approval for children, de-risks pediatric Afrezza development and presents a growth opportunity. In

Tone

Positive 65/100

Event

Regulatory and legal

Published

24 Jun 2026 16:09

Source

Simply Wall Street

Breakthrough T1D backs MannKind’s pediatric Afrezza trial

MannKind Corporation has received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial for Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This multi-center study will evaluate the safety and efficacy of Afrezza, an ultra rapid-acting inhaled

Tone

Positive 67/100

Event

Market update

Published

23 Jun 2026 12:40

Source

Stock Titan

MannKind Awarded Breakthrough T1D Grant to Support Accessibility

MannKind Corporation has been awarded a grant from Breakthrough T1D (formerly JDRF) to support its INHALE-1ST clinical study. This study evaluates the use of Afrezza (insulin human) Inhalation Powder in newly-diagnosed pediatric patients with type 1 diabetes. The grant reinforces

Tone

Positive 71/100

Event

Market update

Published

23 Jun 2026 09:00

Source

GlobeNewswire

MannKind Corp (MNKD) Institutional Confidence

MannKind Corp (MNKD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 17.51% quarter-over-quarter to 67.28%. James Simons is noted as the largest institutiona

Tone

Positive 61/100

Event

Market update

Published

18 Jun 2026 10:10

Source

TradingKey

Why MannKind (MNKD) Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release

MannKind Corporation (MNKD) saw an 8.4% increase after announcing new clinical data for its inhaled insulin, Afrezza, and FUROSCIX at the American Diabetes Association’s 2026 Scientific Sessions, following the U.S. FDA's May 2026 approval of Afrezza for pediatric use. This data a

Tone

Positive 74/100

Event

Regulatory and legal

Published

17 Jun 2026 23:10

Source

Sahm

MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis

MannKind Corp (MNKD) has a current financial score of 7.73, ranking 86th out of 389 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue increased by 15.08% year-over-year to $90.1

Tone

Positive 66/100

Event

Earnings

Published

17 Jun 2026 22:40

Source

TradingKey

MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates

MannKind Corp (MNKD) has an earnings forecast score of 8.25, ranking 143 out of 388 in its industry, with an average analyst price target of $9.00. Based on 8 analysts, the stock receives a "Buy" rating with a target upside of 96.22%. The company's expected revenue for the next q

Tone

Positive 75/100

Event

Earnings

Published

17 Jun 2026 22:11

Source

TradingKey

Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”

Wells Fargo recently raised its price target on MannKind Corporation (MNKD) to $11 from $10, reiterating an Overweight rating, following the FDA's approval of Afrezza for pediatric patients. This approval, expanding Afrezza's use to children aged 6 and older with type 1 and type

Tone

Positive 74/100

Event

Analyst action

Published

13 Jun 2026 15:38

Source

Market source

7 Hidden Penny Stocks to Invest In

This article highlights MannKind Corporation (NASDAQ:MNKD) as one of seven hidden penny stocks to consider. The biopharmaceutical company recently received FDA approval for its Afrezza Inhalation Powder in pediatric patients and has potential for significant development milestone

Tone

Positive 73/100

Event

Regulatory and legal

Published

12 Jun 2026 19:08

Source

Insider Monkey

MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data

MannKind (MNKD) is gaining investor attention after recent positive clinical data for Afrezza and FUROSCIX, alongside pediatric FDA approval for Afrezza. Despite a recent 35.38% share price rebound over 90 days, the year-to-date return is still down 33.04%. The company is conside

Tone

Positive 74/100

Event

Regulatory and legal

Published

12 Jun 2026 02:13

Source

Market source

MannKind gains FDA nod to expand inhaled insulin for children

MannKind Corporation has received FDA approval to expand the label for its Afrezza inhaled insulin. This expansion now includes children and adolescents aged four to 17 with diabetes, making Afrezza the first inhaled insulin option for a pediatric population. The company plans to

Tone

Positive 93/100

Event

Regulatory and legal

Published

11 Jun 2026 22:40

Source

MSN

Should Afrezza Pediatric Approval And New Data Shift MannKind’s (MNKD) Technosphere Platform Investment Narrative?

MannKind (MNKD) recently announced FDA approval of Afrezza for children aged 6 and older, alongside new clinical data for Afrezza and FUROSCIX. This progress, including the advancement of nintedanib DPI into Phase 2 trials for idiopathic pulmonary fibrosis, could significantly al

Tone

Positive 63/100

Event

Regulatory and legal

Published

09 Jun 2026 08:09

Source

Simply Wall Street

ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly

The American Diabetes Association (ADA) conference 2026 featured significant readouts in type 1 and type 2 diabetes. Roche's acmopatide showed promise in T1D by reducing A1C levels and insulin requirements while aiding weight loss. MannKind's inhaled insulin Afrezza received FDA

Tone

Positive 77/100

Event

Market update

Published

09 Jun 2026 06:39

Source

Yahoo